Glycoxidative modification of AA amyloid deposits in renal tissue

Nephrology Dialysis Transplantation

Volumn 15, Issue 3, 2000, Pages 355-365

  Uesugi, Noriko ^a   Sakata, Noriyuki ^a   Nagai, Ryoji ^b   Jono, Tadashi ^b   Horiuchi, Seikoh ^b   Takebayashi, Shigeo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

AA amyloid; CML; Extracellular matrix; Glycoxidative modification; Kidney

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; BETA 2 MICROGLOBULIN; COLLAGEN TYPE 4; GLYCOSYLATED PROTEIN; LAMININ; N (CARBOXYMETHYL)LYSINE; PYRRALINE; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE BASEMENT MEMBRANE; MALE; OXIDATION; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION;

EID: 0034003479     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.3.355     Document Type: Article

References (20)

1. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997; 99: 457-468
2. Munch G, Mayer S, Michaelis J et al. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Acta 1997; 1360: 17-29
3. Miyata T, Inagi R, Iida Y et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of haemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93: 521-528
4. Sakata N, Imanaga Y, Meng J et al. Immunohistochemical localization of different epitopes of advanced glycalion end products in human atherosclerotic lesions. Atherosclerosis 1998; 141: 61-75
5. Takedo A, Yasuda T, Miyata T et al. Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain. Neurosci Lett 1996; 221: 17-20
6. Niwa T, Sato M, Katsuzaki T et al. Amyloid-microglobulin is modified with N-(carboxymethyl)lysine in dialysis related amyloidosis. Kidney Int 1996; 50: 1303-1309
7. Hoshii Y, Kawano H, Gondo T et al. Immunohistochemical study with anti-advanced glycation end-products antibody in murine amyloidosis. Pathol Int 1996; 46: 738-742
8. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alteration in nonenzymatic biochemistry in uremia: origin and significance of 'carbonyl stress' in long term uremic complications. Kidney Int 1999; 55: 389-399
9. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biol Med 1997; 23: 134-147
10. Westermark GT, Norling B, Westermark P. Fibronectin and basement membrane components in renal amyloid deposits in patients with primary and secondary amyloidosis. Clin Exp Immunol 1991; 86: 150-156
11. Ohashi K, Takagawa R, Hara M. Visceral organ involvement and extracellular matrix changes in beta 2-microglobulin amyloidosis-a comparative study with systemic AA and AL amyloidosis. Virchows Arch 1997; 430: 479-487
12. Horiuchi S, Araki N, Morino Y. Immunochemical approach to characterize advanced glycation end products of the Millard reaction; evidence for the presence of a common structure. J Biol Chem 1991; 266: 7329-7332
13. Ikeda K, Higashi T, Sano H et al. N(epsilon)-(carboxymethyl)lysine prolein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996; 35: 8075-8083
14. Mackensen S, Grund KE, Bader R, Bohle A. The influence of glomerular and interstitial factors on the serum creatinine concentration in renal amyloidosis. Virchows Arch A Pathol Pathol Anat 1977; 375: 159-168
15. Shiiki H, Shimokama T, Yoshikawa Y, Toyoshima H, Kitamoto T, Watanabe T. Renal amyloidosis, correlation between morphology, chemical types of amyloid protein and clinical features. Virchows Arch A Pathol Anat Histopathol 1988; 412: 197-204
16. Hara M, Kawai R, Takagawa K. An immunohistochemical study of glycation end products in several different kinds of amyloidosis. Annual Report of the Amyloidosis Research Committee, the Ministry of Health and Welfare of Japan 1995; 108-110
17. Horie K, Miyata T, Maeda K et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004
18. Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 1971; 172: 1150-1151
19. Niwa T, Katsuzaki T, Miyazaki S et al. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187-194
20. Foss GS, Nilsen R, Cornwell GC 3rd, Husby G, Sletten K. A glycosylated Bence Jones protein and its autologous amyloid light chain containing potentially amyloidogenic residues. Scand J Immunol 1998; 47: 348-354